Related Experiment Video
Updated: May 10, 2026
03:42
A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
[Fish and omega-3 fatty acids and heart failure]
1Institutt for klinisk medisin/Farmakologisk institutt, Det medisinske fakultet, Universitetet i Oslo, Norway. k.h.landmark@medisin.uio.no
Summary
Consuming oily fish rich in omega-3 fatty acids may protect against heart failure and reduce mortality in existing heart failure patients. This dietary approach offers cardiovascular benefits, particularly for the elderly.
Area of Science:
- Cardiovascular Science
- Nutritional Epidemiology
- Clinical Cardiology
Context:
- Oily fish are primary sources of marine omega-3 fatty acids, known for cardiovascular benefits.
- Heart failure (HF) is a significant public health concern, particularly in elderly populations.
- Understanding dietary impacts on HF incidence and mortality is crucial for preventative strategies.
Purpose:
- To review the scientific literature on the effects of fish consumption and omega-3 fatty acid intake on heart failure risk.
- To evaluate the impact of omega-3 fatty acids on mortality rates in patients diagnosed with heart failure.
- To explore the underlying mechanisms contributing to the cardioprotective effects of fish and omega-3s.
Summary:
- Recent studies suggest high intake of fish and marine omega-3 fatty acids lowers heart failure incidence and mortality in the elderly.
- A placebo-controlled trial in ~7,000 elderly HF patients showed a 9% mortality reduction with omega-3 fatty acid supplementation.
- These benefits are linked to various hemodynamic and biological mechanisms, supporting fish and omega-3s as cardioprotective agents.
Impact:
- Findings support dietary recommendations for increased fish and omega-3 fatty acid intake for cardiovascular health.
- Provides evidence for omega-3 fatty acids as an adjunct therapy in managing heart failure.
- Highlights the potential of marine omega-3s in reducing heart failure burden and improving patient outcomes.
Related Concept Videos
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
03:38Structure of Lipids
Lipids include a diverse group of compounds that are largely nonpolar in nature. This is because they are hydrocarbons that include mostly nonpolar carbon-carbon or carbon-hydrogen bonds. Non-polar molecules are hydrophobic (“water fearing”), or insoluble in water. Lipids perform many different functions in a cell. Cells store energy for long-term use in the form of fats. Lipids also provide insulation from the environment for plants and animals. For example, they help keep aquatic birds and...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...